Neuroprotection afforded by targeting G protein-coupled receptors in heteromers and by heteromer-selective drugs
G protein-coupled receptors (GPCRs) are the target of hundreds of approved drugs. Although these drugs were designed to target individual receptors, it is becoming increasingly apparent that GPCRs interact with each other to form heteromers. Approved drug targets are often part of a GPCR heteromer,...
Main Authors: | Rafael Franco, Gemma Navarro |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-07-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1222158/full |
Similar Items
-
Angiotensin AT1 and AT2 receptor heteromer expression in the hemilesioned rat model of Parkinson’s disease that increases with levodopa-induced dyskinesia
by: Rafael Rivas-Santisteban, et al.
Published: (2020-08-01) -
G Protein-Coupled Receptor Heteromers as Putative Pharmacotherapeutic Targets in Autism
by: Jon DelaCuesta-Barrutia, et al.
Published: (2020-10-01) -
Investigation of Receptor Heteromers Using NanoBRET Ligand Binding
by: Elizabeth K. M. Johnstone, et al.
Published: (2021-01-01) -
Receptor-Heteromer Investigation Technology and its application using BRET
by: Kevin ePfleger, et al.
Published: (2012-08-01) -
Family A GPCR heteromers in animal models
by: Javier eGonzalez-Maeso
Published: (2014-10-01)